Logo
x

Search

Subscribe Now

Parkinson’s Disease

Kyowa Kirin's Nourianz (istradefylline) Receives FDA's Approval as an Adjunctive Therapy in Patients with Parkinson's Disease

Kyowa Kirin's Nourianz (istradefylline) Receives FDA's Approval as an Adjunctive Therapy in Patients with Parkinson's Disease

  • August 28, 2019
Kyowa Kirin Signs an Exclusive Commercialization Agreement with Hisamitsu for its HP-3000

Kyowa Kirin Signs an Exclusive Commercialization Agreement with Hisamitsu for its HP-3000

  • February 6, 2019
Ventus Therapeutics Reports Results from the P-I Study of VENT-02 in Healthy Volunteers

    Ventus Therapeutics Reports Results from the P-I Study of VENT-02 in Healthy Volunteers

    • April 18, 2024
    Amneal and Zambon Biotech Sign an Exclusive Licensing Agreement for IPX203 to Treat Parkinson’s Disease (PD)

      Amneal and Zambon Biotech Sign an Exclusive Licensing Agreement for IPX203 to Treat Parkinson’s Disease (PD)

      • February 28, 2024
      Supernus Reports the US FDA’s Acceptance to Review SPN-830’s Resubmitted NDA for the Treatment of Off Episodes in Parkinson’s Disease

        Supernus Reports the US FDA’s Acceptance to Review SPN-830’s Resubmitted NDA for the Treatment of Off Episodes in Parkinson’s Dise...

        • November 3, 2023
        Serina Therapeutics Entered into a Merger Agreement with AgeX Therapeutics to Advance its CNS Pipeline Assets

          Serina Therapeutics Entered into a Merger Agreement with AgeX Therapeutics to Advance its CNS Pipeline Assets

          • September 1, 2023
          Amneal Reports P-III Study Results of IPX203 for the Treatment of Parkinson’s Disease

            Amneal Reports P-III Study Results of IPX203 for the Treatment of Parkinson’s Disease

            • August 25, 2023
            Amneal Receives Complete Response Letter on the NDA for IPX203 to Treat Parkinson’s Disease

              Amneal Receives Complete Response Letter on the NDA for IPX203 to Treat Parkinson’s Disease

              • July 4, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.